Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis

NCT03316781 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

262

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: HLX03
DRUG: adalimumab

Sponsor

Shanghai Henlius Biotech